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INTRODUCTION
Members of the Bcl-2 family of apoptotic regulatory proteins are frequently dysregulated in diverse cancers, particularly hematological malignancies such as acute myelogenous leukemia (AML). Such aberrations include over-expression of anti-apoptotic proteins such as Bcl-2, BclxL, and Mcl-1, as well as decreases/loss of pro-apoptotic members such as Bim, Bax, natural born killer (Nbk)/Bcl-2-interacting killer (Bik). [1] [2] [3] The ultimate consequences of these perturbations are defects in apoptosis that lead to enhanced cell survival as well as increased resistance to various chemotherapeutic drugs. To circumvent such problems, several strategies have been developed which directly target anti-apoptotic Bcl-2 family members. Among these is, obatoclax (GX15-070), a small molecule inhibitor that targets all pro-survival Bcl-2 members including Bcl-2, Bcl-xL, Bcl-W, as well as Mcl-1. 4 Preclinical studies demonstrated that obatoclax exhibits potent anti-tumor activity in various cancer cell types including leukemia. 5;6 It is currently undergoing phase I and II clinical evaluation. 7;8 Obatoclax exerts its antitumor activity through multiple mechanisms. For example, it has been shown to trigger apoptosis by dissociating the pro-apoptotic protein Bak from both Mcl-1 4;6 and Bcl-xL 9 in conjunction with release of Bim from Mcl-1 and Bcl-2. 5;9 However, the ability of obatoclax to induce death in Bax/Bak-deficient cells 5 ;10 prompted the search for additional mechanisms of lethality. In this context, obatoclax has been reported to induce autophagy-or necroptosis-dependent cell death.
10;11 Finally, obatoclax may also inhibit cell growth by inducing cell cycle arrest in S-G2 phase. 5 For personal use only. on April 16, 2017. by guest www.bloodjournal.org From Sorafenib was originally developed as a C-Raf and B-Raf inhibitor, but was subsequently shown to inhibit multiple other kinases, including FLT3, VEGFR-2, VEGFR-3, PDGFR-β, c-Kit, among others. 12 It is currently approved for the treatment of refractory renal cell and hepatocellular carcinoma. When administered at standard doses (e.g., 400 mg po BID daily), steady state levels in excess of 10 µM have been reported. 13 To date, interest in sorafenib in AML has focused on mutant FLT3 forms of the disease. 14;15 However, several groups, including our own, have shown that pharmacologically achievable concentrations of sorafenib kill diverse malignant cell types, including wild-type FLT3 human leukemia cells, in association with downregulation of Mcl-1 protein expression. [16] [17] [18] [19] [20] [21] In human leukemia cells, this stems from a translational inhibitory mechanism. 16;22 In this setting, Mcl-1 down-regulation has been shown to play a significant functional role in sorafenib lethality. 16;17;20 In addition to the well-established role of Mcl-1 in opposing sorafenib activity, 16-21 recent evidence suggests that sorafenib lethality may also be attenuated by Bcl-2 and Bcl-xL, 23;24 raising the possibility that an agent capable of inhibiting all three antiapoptotic proteins (i.e.,
Mcl-1, Bcl-2, and Bcl-xL) might be particularly effective in potentiating sorafenib anti-leukemic activity. To test this hypothesis, we have examined anti-leukemic interactions between obatoclax and sorafenib in human leukemia cells, focusing on those with wild-type FLT3. Our results indicate that combined treatment with sorafenib and obatoclax exhibits potent anti-leukemic activity in vitro and in vivo, and suggest that this strategy warrants further investigation. and the National Cancer Institute, NIH (Bethesda, MD). Obatoclax was provided by GeminX, Biotechnologies, Inc. and the National Cancer Institute. HA14-1, gossypol, 3-methyladenine, chloroquine, and bafilomycin A1 were purchased from Sigma Aldrich (St. Louis, MO). All reagents were formulated as recommended by their suppliers.
Assessment of apoptosis.
The extent of cell death was routinely assessed by 7-AAD staining assay as previously described. 29 Parallel studies employing annexin V/PI analysis yielded essentially equivalent results.
Autophagy
EGFP-LC3 fusion cDNA was cut from pEGFP-C2 vector, a gift from Dr. Finkel T (Addgene #24920, Cambridge MA) 30 and sub-cloned into PLVX-puro lentiviral vector (Clontech).
Lentiviral particles were generated as above and used to infect U937 and MV4-11 cells. Cells expressing EGFP-LC3 were sorted by FACS before treatment. After exposure to the designated agents, cells were fixed with 4% paraformaldehyde, mounted onto slides in mounting medium containing DAPI (SouthernBiotech, Birmingham, AL), and analyzed for autophagy using a Zeiss LSM 510 confocal microscope.
Fusion between autophagosomes and lysosomes was assessed by co-localization of LC3
(autophagosome marker) and LAMP1 (lysosome marker) using confocal microscopy. Briefly, cells expressing EGFP-LC3 were fixed as above and permeabilized with 0.25% Triton X-100.
LAMP1 was immuno-detected with anti-LAMP1 antibodies (H5G11; Santa Cruz Biotechnology, Santa Cruz, CA) using Alexa-Fluor-647-conjugated secondary antibodies Immunoprecipitation and immunoblotting. Cells were lysed in CHAPS buffer 16 after which 500 μg of protein lysates were subjected to immunoprecipitation using designated antibodies.
Immunoblotting was performed using the immunoprecipitates or the whole cell lysates as previously described in detail. 29 To examine interactions between sorafenib and obatoclax, U937 cells were exposed to various concentrations of these agents alone or in combination for 48 h, after which the extent of cell death was monitored by the 7-AAD assay. While 1.5 μM obatoclax was only minimally toxic by itself, it substantially increased cell death of pharmacologically achievable concentrations of sorafenib (e.g, 4 -8 μM) ( Figure 1A) . Analogously, the lethality of marginally toxic obatoclax concentrations (e.g., 0.5 -2 μM) was significantly increased by co-exposure to 7.5 μM sorafenib ( Figure 1B ).
RESULTS

Combined
Time course analysis of cells exposed simultaneously to 7.5 μM sorafenib and 1.5 μM obatoclax revealed approximately 30 % cell death at 24 h, and more pronounced lethality after 48-72 h (60-80 %, Figure 1C ). Similar results were obtained with Wright-Giemsa staining or trypan blue assays (data not shown). Median Dose Effect analysis of cells exposed to sorafenib and obatoclax for 48 h at a fixed ratio yielded Combination Index values considerably less than 1.0, indicating a highly synergistic interaction ( Figure 1D ). Enhanced lethality following combined sorafenib/obatoclax exposure was also observed in other leukemia cell lines including the FLT3-ITD-dependent MV4-11, and promyelocytic leukemia HL-60 cells ( Figure 1E ).
Notably, in MV4-11 cells, lower sorafenib concentrations were required (e.g., 75 nM), presumably due to inhibitory effects of sorafenib on FLT3. 14;15 Combined exposure to sorafenib and obatoclax was associated with profound mitochondrial damage, reflected by the pronounced release of cytochrome c and AIF into the cytosol in U937 cells ( Figure 1F ), the marked cleavage/activation of caspases-3, and -9, and PARP in U937 as well as MV4-11 and HL-60 cells ( Figure 1G ), and the pronounced loss in mitochondrial membrane potential (Δψ, supplemental Figure 1A ). In sharp contrast, individual exposure of cells to sorafenib or obatoclax had only minimal effects. Notably, pre-treatment of cells with the pan-caspase inhibitor Q-VD-OPH sharply diminished sorafenib/obatoclax-mediated lethality (Supplemental Figure 1B) .
Combined treatment also markedly reduced cell growth and viability (Supplemental Figure 1C) .
Finally, combined exposure to sorafenib and very low concentrations of obatoclax (75 nM) resulted in a marked decline in U937 cell colony formation, whereas the agents administered alone exerted only modest effects ( Figure 1H ).
Parallel studies using the annexin V/PI assay revealed that co-exposure of human leukemia cells to sorafenib and HA14-1, another BH3-mimetic Bcl-2 antagonist for 24 h also resulted in the marked induction of apoptosis (Supplemental Figure 2A ), in association with the striking release of cytochrome c and AIF into the cytosol (Supplemental Figure 2B ) and cleavage of caspase-3, caspase-9 and PARP (Supplemental Figure 2C ). In addition, Median Dose Effect analysis performed in U937 cells revealed highly synergistic interactions between sorafenib and HA14-1 (Supplemental Figure 2D) analogous to results obtained with sorafenib and obatoclax.
Lastly, sorafenib also enhanced the lethality of the BH3-mimetic gossypol in U937 cells (Supplemental Figure 2E ).
Co-treatment with sorafenib and obatoclax increases lethality in primary AML blasts while largely sparing normal CD34 + cells.
Parallel studies using the 7-AAD assay revealed that simultaneous administration of sorafenib and obatoclax resulted in a significant increase in cell death in primary leukemic blasts isolated from 4 patients with AML (FAB classification M2; 3 patients with wild-type FLT3 and 1 patient with a FLT3-ITD mutation) (Figure 2A ). Similar results were obtained when Wright
Giemsa-stained cells were evaluated (data not shown). Further analysis performed on blasts isolated from patient #1 showed enhanced cleavage of caspase-3 and PARP in cells co-treated with sorafenib and obatoclax compared to cells treated with the agents alone ( Figure 2B ).
Interestingly, exposure to comparable or significantly higher concentrations of sorafenib and obatoclax alone or in combination exhibited minimal lethality toward normal CD34 + cells ( Figure 2C ). Furthermore, the clonogenic potential of primary AML specimens was markedly diminished by combined treatment with sorafenib and obatoclax ( Figure 2D ), whereas the clonogenicity of normal CD34 + cells was largely unaffected ( Figure 2E ).
Sorafenib/obatoclax-mediated lethality involves Bax and Bak
In view of the central roles that the multi-domain proteins Bax and Bak play in apoptosis, 32 activation of these proteins was examined. While treatment with sorafenib (7. Figure 4B ). In contrast, no major changes were noted in the levels of other anti-apoptotic family members i.e., Bcl-2 or Bcl-xL ( Figure 4A ). In addition, very modest downregulation of Bim protein levels was observed following exposure to agents alone or in combination. However, in marked contrast, and consistent with a previous report, 33 Noxa was markedly down-regulated by sorafenib ( Figure 4A ). However, this effect was largely prevented by co-treatment with obatoclax, which by itself modestly increased Noxa protein levels at 6 h, but not at 24 h. To assess the functional significance of Mcl-1 down-regulation in sorafenib/obatoclaxinduced lethality, U937 cells ectopically expressing Mcl-1 were employed. As anticipated, these cells were significantly more resistant than control cells to sorafenib (Supplemental Figure 3C ).
Interestingly, these cells were also significantly more resistant to obatoclax than control cells, although the degree of resistance was less than that observed in the case of sorafenib (Supplemental Figure 3D) . Notably, combined treatment with 7.5 μM sorafenib and 1. Finally, previous studies indicated that the pro-apoptotic protein Noxa may also contribute to cell death induced by treatment involving obatoclax 35;36 or sorafenib 33 in some settings. To determine whether Noxa played a functional role in sorafenib/obatoclax-mediated cell death, U937 cells in which Noxa protein was knocked down with shRNA were employed. In contrast to results involving Bim, a 7-AAD staining assay revealed that U937 cells in which Noxa expression was markedly decreased ( Figure 5F ) remained fully sensitive to sorafenib/obatoclax lethality ( Figure 5E ). Consistent with this finding, no major changes were observed in caspase-3 or PARP cleavage ( Figure 5F ), arguing against the possibility that Noxa plays a major functional role in sorafenib/obatoclax-mediated apoptosis in human leukemia cells.
Autophagy plays a protective role against sorafenib/obatoclax lethality.
Because both sorafenib and obatoclax have been implicated in induction of autophagy in diverse systems, 10;11 we examined whether this process might play a role in sorafenib/obatoclax antileukemic activity. As shown in Figure 6A , obatoclax elicited a rapid and robust induction of LC3 processing in U937 cells, which occurred as early as 2 h after treatment and persisted over the ensuing 20 h post-treatment. This effect was also observed with combined exposure to obatoclax and sorafenib, although it was slightly less pronounced. However, sorafenib alone had no discernible effect on LC3 processing. Similar results were obtained in HL-60 cells (Supplemental Figure 5F ). In contrast, no major changes were observed in the expression of beclin-1 (BCN1) or ATG5 protein levels with any treatments. Consistent with LC-3 processing, confocal microscopic analysis of U937 cells expressing an LC3-GFP fusion protein revealed a marked increase in autophagosomes, as indicated by enhanced LC3-GFP punctate formation/aggregation in cells exposed for 6 h to obatoclax alone or in combination with sorafenib (but not to sorafenib alone) ( Figure 6B ). Similar results were observed in MV4-11 cells (Supplemental Figure 5A) . Furthermore, immunofluorescence studies using LC3-EGFP (an autophagosome marker) and LAMP1 (a lysosome marker) revealed marker co-localization after treatment with obatoclax alone or in combination with sorafenib, indicating fusion between autophagosomes and lysosomes ( Figure 6C and Supplemental Figure 5B ). Furthermore p62/SQSTM1, a marker of autophagy flux, significantly decreased following treatment (24 h) with obatoclax alone or obatoclax/sorafenib (Supplemental Figure 5C ). Interestingly interference with autophagy using a series of autophagy inhibitors (e.g., 3MA, chloroquine, or bafilomycin A1) strikingly potentiated sorafenib/obatoclax lethality ( Figure 6D ). In contrast, these agents did not result in significant increases in the lethality of obatoclax or sorafenib alone (Supplemental Figure 5D) were significantly down-regulated by either agents alone or in combination (data not shown).
These events correlated with significantly prolonged survival of tumor-bearing mice treated with sorafenib/obatoclax and, to a lesser extent, with sorafenib alone ( Figure 7E ). In contrast, obatoclax administered alone did not prolong survival. These findings were confirmed in studies of mice inoculated with luciferase-expressing U937 cells (Supplemental Figure 7A) . Finally, treatment with agents alone or in combination did not lead to major changes in mouse weights or in white or red blood cell counts (Supplemental Figures 7B and 7C respectively), nor were changes in behavior or hair loss observed. Together, these findings indicate that combined treatment with sorafenib and obatoclax significantly reduces tumor growth in association with, Mcl-1 down-regulation, and prolongs survival in leukemia-bearing mice.
For It is interesting that obatoclax administered either alone or in combination with sorafenib, induced a marked increase in autophagic markers, including induction of LC3-II and formation of GFP-LC3 punctate/aggregates in human leukemia cells. Notably, LC3 processing was slightly reduced in cells exposed to combined treatment compared to obatoclax alone. However, the pronounced increase in LC3-GFP punctuate formation and fusion between autophagosomes and lysosomes observed with combined treatment was similar to that seen with obatoclax alone.
Autophagy represents a versatile and dynamic cellular response to diverse noxious stimuli that, in most cases protects cells, but can also, under some circumstances, contribute to their demise.
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It should be noted that increases in autophagic markers such as processed LC3 or the formation markedly potentiated sorafenib/obatoclax-mediated lethality, argue for a protective role for autophagy induction in the current setting. Finally, these findings raise the possibility that clinically relevant autophagy inhibitors (e.g., chloroquine) may further enhance sorafenib/obatoclax anti-leukemic activity.
In addition to marked in vitro interactions, the sorafenib/obatoclax regimen elicited a pronounced reduction in tumor growth in a leukemia xenograft murine model accompanied by a significant increase in survival. Importantly, these events were also associated with Mcl-1 downregulation and enhanced apoptosis in leukemia cells exposed to these agents in vivo. They also suggest that sufficiently high sorafenib and obatoclax concentrations can be achieved in vivo to recapitulate at least some of the actions observed in vitro e.g Mcl-1 down-regulation.
Interestingly, little toxicity was observed in animals with the doses and schedules used in these studies. Previous studies have described the development of neurotoxicity when obatoclax was administered intravenously to nude mice. 6 We observed similar phenomena (data not shown), but this problem was largely resolved by employing intramuscular injections. Although the ability of this regimen to eradicate leukemia stem cells remains to be determined, the present in vivo findings, along with in vitro evidence that the sorafenib/obatoclax regimen is active against at least some primary AML cells and exhibits minimal toxicity toward normal CD34 + cells, suggest that this strategy warrants further consideration in AML. Accordingly, plans to evaluate the tolerability of this regimen through a phase I trial in patients with refractory AML, including patients with either FLT3-ITD-mutated or -wild-type disease, are currently underway. 
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The authors have no conflict of interest to disclose. (A) U937 cells were exposed to the designated concentrations of sorafenib alone (empty circles) or in combination with 1.5 μM obatoclax (Ob, filled circles) for 48 h after which the percentage of apoptotic cells was determined by the 7-AAD staining assay. * = significantly greater than sorafenib alone; P < 0.05; ** = P < 0.01. (B) U937 cells were exposed to the designated concentrations of obatoclax alone (empty circles) or in combination with 7.5 µM sorafenib (filled circles), for 48 h after which cell death was determined as above. * = significantly greater than obatoclax alone; P < 0.02; ** = P < 0.01. (C) Cells were exposed to sorafenib (7.5 μM) and obatoclax (1.5 μM) alone or in combination for the indicated intervals, after which the percentage of dead cells was determined as above. * = significantly greater than either agent alone; P < 0.05; ** = P < 0.002. (D) Median Dose Effect analysis of cell death induction by sorafenib and obatoclax. U937 cells were exposed to varying concentrations of obatoclax and sorafenib at a fixed ratio (1:5), for 48 h after which extent of cell death was monitored with the 7-AAD staining assay. Combination Index (C.I.) values were determined in relation to the Fractional Effect using a commercially available software program as described in Methods. C.I. values < 1.0 correspond to a synergistic interaction. (E) MV4-11 and HL-60 cells were exposed to sorafenib (75 nM and 7.5 μM respectively) and obatoclax (0.5 μM and 2 μM respectively), either individually or in combination for 48 h, after which the percentage of dead cells was determined by the 7-AAD assay. * = significantly greater than values for either agent alone; P < 0.02. (F) U937 cells were exposed to sorafenib (7.5 μM) and obatoclax (1.5 μM) alone or in while knockdown of these molecules markedly attenuates cell death. U937 cells were exposed to sorafenib (7.5 μM) and obatoclax (1.5 μM) alone or in combination for 30 h after which cells were lysed in buffer containing 1% CHAPS; conformationaly changed Bax (A) and Bak (B) proteins were immunoprecipitated using anti-Bax 6A7 and anti-Bak Ab1 antibodies respectively and subjected to Western blot analysis using polyclonal Bax or Bak antibodies.
Input lysates were also subjected to Western blot analysis to monitor Bax and Bak protein levels.
(C) U937 cells stably transfected with shRNA against GFP (shGFP), Bax (shBax), or Bak (shBak) were treated with sorafenib (7.5 μM) and obatoclax (1.5 μM), for 48 h after which Bim (shBim#1 and shBim#2), and one clone from each transfection was selected. These and shGFP control cells were exposed to sorafenib (7.5 μM) and obatoclax (1.5 μM) for 48 h after which Western blot analysis was performed. (B) shBim#1 and shBim#2 cells were treated with sorafenib and obatoclax as above for 6 h after which the cytosolic fraction was isolated and subjected to Western blot analysis. (C) shBim#1, shBim#2, and shGFP cells were exposed to sorafenib and obatoclax as in (A) for 48 h after which the extent of cell death was monitored by the 7-AAD staining assay. * = significantly less than values for shGFP control cells; P < 0.02. exposed to sorafenib (7.5 μM) and obatoclax (1.5 μM) for the designated intervals after which protein lysates were prepared and subjected to Western blot analysis. (B) U937 cells were stably transfected with LC3-EGFP, and EGFP positive cells were sorted by FACS and exposed to sorafenib and obatoclax for 6 h. Cells were then fixed and subjected to confocal microscopy as described in Methods. (C) Representative images with confocal microscopy of co-localized LC3-GFP (Green) and LAMP1 (red) in U937 cells following 6-h treatment with sorafenib (7.5 μM) and obatoclax (1.5 μM). Enlarged images of outlined areas are shown in Supplemental
Figure 5B. (D) U937 cells were pretreated with 3-MA (2.5 mM), chloroquine (CQ; 40 μM), or bafilomycin A (BAF; 75 nM) for 30 min, and exposed to sorafenib (7.5 μM) and obatoclax (1.5 μM) alone or in combination for an additional 16 h after which the extent of cell death was monitored by the 7-AAD assay. * = significantly greater than values for cells not exposed to 3MA, CQ, or BAF; P < 0.01. Alternatively, protein lysates were prepared from the indicated samples and subjected to Western blot analysis (E). (F) U937 cells in which VPS34 was stably knocked down with lentiviruses-mediated shRNA and their control scrambled sequence counterparts (NC) were exposed to sorafenib (7.5 μM) ± obatoclax (1.5 μM) for 24 h, after which the extent of cell death was determined using the 7-AAD assay. * = significantly different from values obtained for control cells (P < 0.05). 
